title: [Osteoporosis, estrogens, and bone metabolism. Implications for chronic renal insufficiency].
abstract: The relationship between estrogens, bone metabolism and osteoporosis is well known. Chronic renal failure in women is associated with menstrual disorders, lower bone mineral density and increased risk of fractures. However, most studies on renal osteodystrophy have not taken into account the role of oestrogen deficiency, its interaction, and the possible benefits of hormone replacement therapy (HRT) in uremic women. According to these limitations and the actual evidence of benefits and risks of HRT, we conclude that: a) Osteoporosis must be evaluated as a part of renal osteodystrophy; b) HRT would be considered in women with climateric symptoms and osteoporosis, and should not be used for prevention of cardiovascular disease, and c) Clearly we need to do more studies related to osteoporosis and estrogens in CRF, but right now we have to try to optimize bone turnover in our uremic patients.
authors.affiliation: Servicio de Metabolismo Oseo y Mineral, Instituto Reina Sofía de Investigación, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo.
authors.forename: J B
authors.initials: JB
authors.lastname: Díaz López
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez Rodríguez
authors.forename: B
authors.initials: B
authors.lastname: Ramos
authors.forename: C
authors.initials: C
authors.lastname: Caramelo
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez García
authors.forename: J B
authors.initials: JB
authors.lastname: Cannata Andía
mesh_terms: D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000378:metabolism*; D001943:Breast Neoplasms / Q000139:chemically induced; D002277:Carcinoma / Q000139:chemically induced; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology; D016889:Endometrial Neoplasms / Q000139:chemically induced; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000502:physiology* / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D008599:Menstruation Disturbances / Q000209:etiology; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000378:metabolism*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D017698:Postmenopause; D012307:Risk Factors; D019851:Thrombophilia / Q000139:chemically induced; D014511:Uremia / Q000209:etiology
chemical_list: D004967:Estrogens